Current Clinical Trials
Canine Osteosarcoma Autologous Therapeutic Immunotherapy
Veterinary Cancer Group is currently enrolling cases for a partially funded clinical trial to evaluate safety and efficacy of an autologous (made from a patient’s own tumor) therapeutic immunotherapy vaccine (K9-ACV) in combination with amputation and chemotherapy for the treatment of canine appendicular osteosarcoma. This novel concept is being explored to examine extended lifespan beyond standard of care for canine cancer patients. The current standard of care for canine appendicular osteosarcoma patients is amputation and chemotherapy (generally either carboplatin chemotherapy or Adriamycin chemotherapy).
This immunotherapy vaccine is provided by MediVet Biologics (www.medivetbiologics.com) and will be available via a convenient visit to your treating veterinarian VCG oncologist at the Woodland Hills, South Bay or Tustin locations. This immunotherapy vaccine is not currently being offered at our Culver City location.
Inclusion criteria for this trial
(this list is meant to be a guide and is not exhaustive – final inclusion/exclusion is determined by the on site trial investigator.)
- Canine patients who have been diagnosed or presumptively diagnosed with osteosarcoma of the limbs
- Canine patients who have not yet undergone amputation for osteosarcoma (this is critical for trial inclusion)
- Owners must elect amputation and chemotherapy (carboplatin chemotherapy) for their dog in addition to receiving the autologous tumor vaccine (K9 ACV).
- No pulmonary metastatic disease (spread to the lungs)
- No additional major medical conditions that would prevent a patient from undergoing surgery and chemotherapy
(Prior to acceptance into any trial, all candidates are required to have a consultation to determine eligibility. The fee for the consultation is the responsibility of the pet owner.)
Visit this link for more information about current pet clinical trials:
American Veterinary Medical Association's Animal Health Studies Database.
(edited January 2019)